Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
deals
8
×
detroit blog main
detroit top stories
eli lilly
8
×
indiana blog main
indiana top stories
life sciences
national
8
×
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
startups
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
biotech
cancer
cancer immunotherapy
clinical trials
fda
novartis
pfizer
takeda pharmaceutical
alzheimer's disease
amgen
bristol-myers squibb
What
bio
roundup
drug
companies
pharmaceutical
alzheimer’s
buy
drugs
growing
nash
new
news
price
typically
acquisitions
alliance
appetite
approval
approved
bails
biggest
biogen’s
biopharmaceutical
black
brand
bread
bridgebio
bristol
build
butter
buyout
calls
cancer
capital
car
cash
ceo
changing
color
company’s
Language
unset
Current search:
national
×
deals
×
" eli lilly "
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
Bio Roundup: #JPM19 Notes, Loxo Buyout, Black Diamond’s Cash & More
@xconomy.com
5 years ago
Bio Roundup: Midterm Fallout, Alzheimer’s Search, Postpartum Panel